氯氮平联合利培酮对精神分裂症患者炎症因子水平及阳性与阴性症状量表评分的影响

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (399 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effects of Clozapine combined with Risperidone on serum inflammatory factor levels and positive and negative symptom scale(PANSS)scores in patients with schizophrenia(SZ),in order to guide the formulation of clinical treatment measures and promote clinical benefit in patients with SZ.Methods A total of 80 SZ patients admitted to Jiangxi Honorary Military Preferential Treatment Hospital from January 2020 to August 2022 were selected as the study objects,and they were divided into control group(treated with Clozapine)and observation group(treated with Clozapine combined with Risperidone)according to random number table method,with 40 cases in each group.The therapeutic effect,PANSS score and serum inflammatory factor levels were compared between the two groups.Results The total effective rate of observation group was higher than that of control group,and the difference was statistically significant(P＜0.05).After treatment,the level of serum interleukin-13 in observation group was higher than that in control group,and the level of negative symptoms,positive symptoms,general psychiatric score,total score of PANSS and serum tumor necrosis factor-α were lower than that in control group,and the differences were statistically significant (P＜0.05).There was no significant difference in the total incidence of adverse drug reactions between the two groups(P＞0.05).Conclusion Risperidone combined with Clozapine has a significant effect on SZ,which can effectively reduce PANSS score and regulate the level of inflammatory factors.

Key words： Schizophrenia Clozapine Risperidone Inflammatory factors

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2024/V31/I15/36

[1]	董芳，臧彦楠，姜涛，等.氯氮平在精神分裂症患者的群体药代动力学及其影响因素研究[J].中国临床药理学杂志，2020，36（21）：3433-3436.
[2]	Chand GB，Singhal P，Dwyer DB，et al.Schizophrenia Imaging Signatures and Their Associations With Cognition，Psychopathology，and Genetics in the General Population[J].Am J Psychiatry，2022，179（9）：650-660.
[3]	李华.电针联合氯氮平治疗难治性精神分裂症的疗效观察[J].当代医学，2022，28（6）：55-57.
[4]	Yeh TC，Correll CU，Yang FC，et al.Pharmacological and nonpharmacological augmentation treatments for Clozapineresistant schizophrenia：A systematic review and network meta-analysis with normalized entropy assessment[J].Asian J Psychiatr，2023，79：103375.
[5]	桂秀，陶璃娜，乔娟，等.利培酮联合活血化瘀汤治疗脑卒中后抑郁的疗效及对脑部血液流变学和血清GDNF、5-HT 的影响[J].疑难病杂志，2023，22（9）：914-918.
[6]	中华医学会精神科分会.中国精神疾病分类与诊断标准（CCMD-3）[M].济南：山东科学技术出版社，2001：75-78.
[7]	舒良.精神分裂症防治指南[M].北京：北京大学医学出版社，2007：35-38.
[8]	蒲城城，黄冰洁，苗齐，等.阴性症状评估量表4 条目中文版在轻中度精神分裂症患者中的信效度研究[J].中华精神科杂志，2020，53（6）：508-511.
[9]	Veeneman RR，Vermeulen JM，Abdellaoui A，et al.Exploring the Relationship Between Schizophrenia and Cardiovascular Disease：A Genetic Correlation and Multivariable Mendelian Randomization Study[J].Schizophr Bull，2022，48（2）：463-473.
[10]	Campeau A，Mills RH，Stevens T，et al.Multi-omics of human plasma reveals molecular features of dysregulated inflammation and accelerated aging in schizophrenia[J].Mol Psychiatry，2022，27（2）：1217-1225.
[11]	Forte A，Pompili M，Imbastaro B，et al.Effects on suicidal risk：Comparison of Clozapine to other newer medicines indicated to treat schizophrenia or bipolar disorder[J].J Psychopharmacol，2021，35（9）：1074-1080.
[12]	Filts Y，Litman RE，Martínez J，et al.Long-term efficacy and safety of once-monthly Risperidone ISM～R in the treatment of schizophrenia：Results from a 12-month open-label extension study[J].Schizophr Res，2022，35（239）：83-91.
[13]	李洁，李新纯，李杰，等.脑心同治针刺法联合利培酮对精神分裂症攻击行为及认知功能的临床疗效观察[J].湖南中医药大学学报，2020，40（10）：1244-1248.
[14]	Patlola SR，Donohoe G，McKernan DP.Anti-inflammatory effects of 2ndgeneration antipsychotics in patients with schizophrenia：Asystematicreview and meta-analysis[J].J Psychiatr Res，2023，160：126-136.
[15]	Wang XY，Chan HY，Lin CH.Time to Rehospitalization for Different Oral Risperidone Dosing Frequencies in Patients With Schizophrenia A 17-Year Retrospective Cohort Study[J].J Clin Psychopharmacol，2022，42（2）：133-139.
[16]	严国建，何昌九，胡萱怡，等.氟西汀联合利培酮对精神分裂症患者血脂代谢、认知中记忆维度和血清神经营养因子的影响[J].现代生物医学进展，2021，21（16）：3151-3154，3159.
[17]	Moazen-Zadeh E，Bayanati S，Ziafat K，et al.Vortioxetine as adjunctive therapy to Risperidone for treatment of patients with chronic schizophrenia：A randomised，double-blind，placebo-controlled clinical trial[J].J Psychopharmacol，2020，34（5）：506-513.
[18]	盛磊，戴立磊，高燕梅，等.枸橼酸坦度螺酮联合利培酮治疗精神分裂症患者远期疗效的对照研究[J].神经损伤与功能重建，2022，17（8）：484-487.
[19]	Maffioletti E，Valsecchi P，Minelli A，et al.Association study between HTR2A rs6313 polymorphism and early response to Risperidone and olanzapine in schizophrenia patients[J].Drug Dev Res，2020，81（6）：754-761.
[20]	吕文，杨荣梅，陈梅芳.奥氮平联合利培酮对精神分裂症患者代谢及疗效的影响[J].国际精神病学杂志，2020，47（6）：1138-1141.
[21]	Moazen-Zadeh E，Bayanati S，Ziafat K，et al.Vortioxetine as adjunctive therapy to Risperidone for treatment of patients with chronic schizophrenia：A randomised，double-blind，placebo-controlled clinical trial[J].J Psychopharmacol，2020，34（5）：506-513.
[22]	阿拉木斯.阿立哌唑联合利培酮治疗难治性精神分裂症患者的有效性及安全性[J].中国当代医药，2023，30（1）：100-102.
[23]	骆晓宏，于成盼，马书玉.精神障碍患者合并用药对氯氮平血药浓度的影响研究[J].中国医药科学，2022，12（13）：159-162.
[24]	陶敏，杨培锋.氯氮平联合阿立哌唑在精神分裂症患者中的应用效果[J].中国当代医药，2022，29（31）：102-104.
[25]	朱淼，尹岸民，张东良.奥氮平与利培酮对精神分裂症患者血清BDNF、NGF、IL-6 水平的影响及临床应用效果比较[J].医学临床研究，2020，37（9）：1340-1342，1346.